Business Insurance: Creams cut pain, but price is the rub
Topical creams are becoming part of the mix of pain treatment options as doctors look for alternatives to addictive opioids.
Topical creams are becoming part of the mix of pain treatment options as doctors look for alternatives to addictive opioids.
Explore the proposed changes to California Workers' Compensation regulations and their potential impacts on workers, employers, and the broader system. Stay informed about how these shifts could reshape the future of compensation policies in the state.
FairPay Flex, Enlyte’s specialty bill review solution, offers significant savings potential for workers' compensation medical bill review. Here are some expert tips and tricks to make the most of this powerful tool.
Buprenorphine, a Schedule III controlled substance approved by the U.S. Food and Drug Administration (FDA), is increasingly being considered for pain management in workers' compensation cases. This partial opioid agonist offers a unique profile that balances effective pain relief with a lower risk of abuse and dependence compared to full opioid agonists.
Enhance your specialty bill review workflow with Enlyte's FairPay Flex. Learn how our dedicated team can resolve disputes and streamline processes.
Mitchell today announced the latest release of its Plugged-In: EV Collision Insights report. This edition features an overview of the most notable annual trends in battery electric vehicle (BEV), mild hybrid electric vehicle (MHEV) and plug-in hybrid electric vehicle (PHEV) collision claims. Following a second year of record sales for new cars with electrified powertrains, claims frequency for repairable BEVs rose to 2.71% in the U.S. and 3.84% in Canada in 2024, a year-over-year increase of 38% and 34% respectively.
Claims frequency for collision-damaged, repairable battery electric vehicles (BEVs) rose to 2.71% in the U.S. and 3.84% in Canada in 2024, a year-over-year increase of 38% and 34% respectively. CNBC reported that BEVs and hybrids represented 20% of all new U.S. vehicle sales in 2024, and Cox Automotive is predicting that number to climb to 25% in 2025 despite U.S. policy changes that could hinder BEV adoption.